SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION"

Transcription

1 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Driclor Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Aluminium Chloride Hexahydrate 20% w/w For a full list of excipients, see section PHARMACEUTICAL FORM Solution for topical application 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Driclor is indicated for the treatment of hyperhidrosis of the armpits (axillae), the hands and the feet. 4.2 Posology and method of administration Driclor is for application to the axillae, palms of the hands or soles of the feet. Before applying aluminium chloride hexahydrate, the affected area should be dried thoroughly to avoid burning of the skin (see Warnings and Precautions). Apply Driclor last thing at night after drying the affected areas carefully. Wash off in the morning. Do not re-apply the product during the day.

2 Initially the product may be applied each night until sweating stops during the day. The frequency of application may then be reduced to twice a week or less. 4.3 Contraindications Hypersensitivity to the active substance or to any of the excipients. 4.4 Special warnings and precautions for use Aluminium chloride hexahydrate reacts with water to produce hydrochloric acid. Therefore the areas to be treated should be completely dry before application to avoid skin burning. Application should be restricted to the affected area(s) only. Driclor should not be applied to skin that has been shaved within 12 hours or which is broken or irritated. Hair removal products should not be used on areas to be treated within 12 hours before or after applying Driclor. Avoid contact with eyes, nostrils, mouth or other mucous membranes. In case of accidental contact with the eyes or other mucous membranes, rinse well with water. Avoid direct contact with clothing, jewellery and polished metal surfaces. 4.5 Interaction with other medicinal products and other forms of interaction None known 4.6 Fertility, pregnancy and lactation Pregnancy There are no data from the use of topical aluminium chloride hexahydrate in pregnant women.

3 Studies in animals have shown reproductive toxicity following oral and parenteral administration (see Non-Clinical Information). Due to the nature of aluminium it is unlikely that it penetrates the skin, therefore no effects during pregnancy are anticipated with use of aluminium chloride hexahydrate solution. Lactation It is unknown whether topical aluminium chloride hexahydrate is excreted in human milk. Due to the nature of aluminium, it is unlikely that it penetrates the skin, therefore no effects on the breast-fed newborn/infant are anticipated with use of aluminium chloride hexahydrate solution. If aluminium chloride hexahydrate is used when breast-feeding, care should be taken not to get any solution on the breasts to ensure that the baby is not accidentally exposed to aluminium chloride hexahydrate. If any of the solution does get on the breasts, the patient should be instructed to wash-off all traces before beginning breastfeeding. 4.7 Effects on ability to drive and use machines None 4.8 Undesirable effects Driclor may cause irritation which may be alleviated by use of a weak corticosteroid cream. Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency. Frequencies are defined as: very common ( 1/10), common ( 1/100 and <1/10), uncommon ( 1/1,000 and <1/100), rare ( 1/10,000 and <1/1,000), very rare (<1/10,000), and not known (cannot be estimated from the available data). Clinical Trial Data Skin and Subcutaneous Tissue Disorders Very common: Application site irritation Post Marketing Data Immune System Disorders Not known: Application site hypersensitivity including application site dermatitis

4 Skin and Subcutaneous Tissue Disorders Not known: Application site reactions including pain, pruritus, erythema, rash and skin burning sensation 4.9 Overdose Symptoms and signs Application more frequently than recommended may increase the severity of skin irritation. Ingestion can cause nausea, vomiting, diarrhoea and burning in the mouth and throat. The formulation contains a significant quantity of ethanol. Systemic absorption of this should be considered a possibility in the event of overdosage. Treatment In the event of accidental oral ingestion rinse the mouth with plenty of water. Further management should be as clinically indicated or as recommended by the national poisons centre, where available. 5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Aluminium chloride hexahydrate acts locally, in the stratum comeum and in the terminal duct, to relieve hyperhidrosis. ATC Code D11AA Pharmacotherapeutic Group: Dermatologicals, Other dermatological preparations, Antihidrotics. Mechanism of Action Aluminium chloride hexahydrate is acidic and is thought to act by diffusing into the sweat ducts where on neutralisation it forms gelatinous hydroxides which obstruct the flow of sweat. The antiperspirant effect of aluminium chloride hexahydrate is partly explained by production of mechanical blockage in the eccrine sweat duct.

5 Following application, aluminium is found in the stratum corneum and intraluminally in the terminal duct. It has been suggested that the metal ions form precipitating complexes with the mucopolysaccharides and carboxyl groups of the stratum corneum. This causes damage to the luminal epithelial cells, generating an obstructive conglomerate which plugs the acrosyringium. Studies of long-term treatment with aluminium chloride have shown that prolonged application leads to functional and structural degeneration of the eccrine acini, accounting for the observed progressive decrease in severity of hyperhidrosis during treatment. 5.2 Pharmacokinetic properties Absorption Due to the effective absorption barriers of gut, lung and skin, the absorption rates of aluminium via the oral, inhalational and dermal routes are %, 1.5-2%, and approximately 0.01% respectively. Distribution About 90% of plasma aluminium is bound to transferrin, 7% occurs as citrate, and less than 1% as phosphate and hydroxide. Elimination More than 99% of orally ingested aluminium is eliminated via faeces. Of the small amounts of aluminium absorbed from the gastrointestinal tract, more than 95% is excreted in the urine. 5.3 Preclinical safety data Not applicable 6 PHARMACEUTICAL PARTICULARS

6 6.1 List of excipients %w/w Ethanol Purified water Incompatibilities None 6.3 Shelf life a) For the product as packaged for sale 3 years b) After first opening the container Comply with expiry date 6.4 Special precautions for storage Store in a cool place below 25 ºC. Keep away from naked flame. Store upright. 6.5 Nature and contents of container High density polyethylene bottle with roll-on applicator.

7 Pack size: 30ml, 40ml, 45ml, 50ml and 60ml High density polyethylene bottle with polypropylene cap. LDPE housing containing polypropylene roller-ball with over-cap for self-assembly. Pack Size: 75ml Not all pack sizes may be marketed. 6.6 Special precautions for disposal The 75ml pack should be assembled according to the instructions in the package leaflet. 7 MARKETING AUTHORISATION HOLDER Beecham Group plc, trading as Stiefel 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom 8 MARKETING AUTHORISATION NUMBER(S) PL 00079/ DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

8 31 st August DATE OF REVISION OF THE TEXT 20/02/ DOSIMETRY (IF APPLICABLE) 12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)

EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013

EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013 EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken

More information

ZOVIRAX Cold Sore Cream

ZOVIRAX Cold Sore Cream Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face

More information

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Aknemycin Solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 10 g of solution contains 0.2 g of erythromycin. Structural formula of

More information

NEUROTONE THR 00904/0005 UKPAR

NEUROTONE THR 00904/0005 UKPAR NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet

More information

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665 Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient

More information

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) 1 PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) PHOSPHATE-SANDOZ PHOSPHATE-SANDOZ Tablets are a high dose phosphate supplement containing sodium phosphate monobasic. The CAS registry number

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Trimega 1000 mg Capsules Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 1000 mg Omega-3-acid ethyl esters 90, comprising

More information

Public Assessment Report. Loperamide 2mg Capsules. Loperamide hydrochloride PL 31308/ Max Remedies Ltd. Table of Contents

Public Assessment Report. Loperamide 2mg Capsules. Loperamide hydrochloride PL 31308/ Max Remedies Ltd. Table of Contents Public Assessment Report Loperamide 2mg Capsules Loperamide hydrochloride PL 31308/0002-3 Max Remedies Ltd Table of Contents Page Lay Summary 2 Scientific Discussion 3 Overall Conclusion And Risk Benefit/Analysis

More information

Draft presentation: Summary of product characteristics

Draft presentation: Summary of product characteristics Draft presentation: Summary of product characteristics What is it and what does it contain? Olayinka Fasanya Medical information - Information compliance and consistency An agency of the European Union

More information

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013. The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013 Havrix 720 Junior 1 NAME OF THE MEDICINAL PRODUCT Havrix 720 Junior 2 QUALITATIVE

More information

SUMMARYOF PRODUCT CHARACTERISTICS

SUMMARYOF PRODUCT CHARACTERISTICS SUMMARYOF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Excis 10 mg/ml concentrate for solution for fish treatment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Cypermethrin

More information

NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate.

NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate. NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate. PRESENTATION Eye Drops: NAPHCON-A Eye Drops are a combination of an antihistamine (pheniramine maleate) and a decongestant

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Isotrexin 2% + 0.05% w/w Gel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Erythromycin Isotretinoin 2.00% w/w 0.05% w/w Excipients: Contains

More information

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE) European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMEA/HMPC/745582/2009 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH

More information

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS European Medicines Agency Evaluation of Medicines for Human Use London, 4 September 2008 Doc. Ref. EMEA/HMPC/368600/2007 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON

More information

Ibuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel

Ibuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel Ibuprofen 10% w/w gel Nurofen Maximum Strength 10 % Gel PL 10972/0089 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics

More information

Summary of Product Characteristics

Summary of Product Characteristics Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT ACEGON, 50 microgram/ml, solution for injection for cattle. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active

More information

4 Clinical Particulars

4 Clinical Particulars SUMMARY OF PRODUCT CHARACTERISTICS 1 Name of the Medicinal Product Procyclidine Syrup 5mg/5ml 2. Qualitative and Quantitative Composition Each 5ml dose contains 5mg Procyclidine Hydrochloride BP. 3. Pharmaceutical

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride) UK Licence No: PL 20346/0008 Viridian Pharma Ltd LAY SUMMARY Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride)

More information

Read all of this leaflet carefully because it contains important information for you.

Read all of this leaflet carefully because it contains important information for you. Package Leaflet: Information for the User Thioctacid 600 HR, Film-coated tablets For use in adults Active substance: Alpha-lipoic acid Read all of this leaflet carefully because it contains important information

More information

Summary of Product Characteristics Medical Helium

Summary of Product Characteristics Medical Helium Summary of Product Characteristics Medical Helium www.uk.airliquide.com 1. NAME OF THE MEDICINAL PRODUCT Medical Helium 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Helium BP 1988 100%. 3. PHARMACEUTICAL

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Aknemycin Plus 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 100 g of solution contains: Erythromycin 4.0 g, Tretinoin 0.025 g. For a full

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Thorens 10000 I.U./ml oral drops, solution Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml oral solution (50 drops) contains 10 000 I.U.

More information

SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS

SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Steps taken after authorisation

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tantum Verde P 3 mg lozenges, eucalyptus taste Benzydamine Hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tantum Verde P 3 mg lozenges, eucalyptus taste Benzydamine Hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Tantum Verde P 3 mg lozenges, eucalyptus taste Benzydamine Hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid

Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid Package Leaflet: Information for the User Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid For use in adults Active substance: Alpha-lipoic acid, Trometamol salt (1:1) Read all

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because

More information

UKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3

UKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3 Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation Page 13 Summary of Product Characteristics

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. <invented name> 1 mg Ear drops, solution Ciprofloxacin

PACKAGE LEAFLET: INFORMATION FOR THE USER. <invented name> 1 mg Ear drops, solution Ciprofloxacin PACKAGE LEAFLET: INFORMATION FOR THE USER 1 mg Ear drops, solution Ciprofloxacin Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

Medical Gas Data Sheet (MGDS) 5% carbon dioxide/air medical gas mixture

Medical Gas Data Sheet (MGDS) 5% carbon dioxide/air medical gas mixture Medical Gas Data Sheet (MGDS) 5% carbon dioxide/air medical gas mixture Essential safety information Summary of Product Characteristics (SPC) pages 2-5 Additional Safety Information pages 6-7 BOC: Living

More information

Community herbal monograph on Commiphora molmol Engler, gummi-resina

Community herbal monograph on Commiphora molmol Engler, gummi-resina 12 July 2011 EMA/HMPC/96911/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Commiphora molmol Engler, gummi-resina Final Discussion in Working Party on Community monographs

More information

GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS

GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12

More information

2 What you need to know before you have Ampiclox

2 What you need to know before you have Ampiclox Reason for update: GDS 14 & QRD Updates Response to questions for variation update section 4.1 of SPC MHRA Submission Date: 6 November 2014 MHRA Approval Date: Text Date: October 2014 Text Issue and Draft

More information

PATIENT INFORMATION LEAFLET: CENTRUM. Read the contents of this leaflet carefully before you start using CENTRUM, because it

PATIENT INFORMATION LEAFLET: CENTRUM. Read the contents of this leaflet carefully before you start using CENTRUM, because it PATIENT INFORMATION LEAFLET: CENTRUM Page 1 of 7 This leaflet tells you about CENTRUM tablets. Read the contents of this leaflet carefully before you start using CENTRUM, because it contains important

More information

Prescribing Information

Prescribing Information The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it. Omacor Prescribing Information 1 NAME OF THE MEDICINAL PRODUCT OMACOR, 1000 mg, soft

More information

Medical Gas Data Sheet (MGDS) 9% helium/35% oxygen/nitrogen medical gas mixture

Medical Gas Data Sheet (MGDS) 9% helium/35% oxygen/nitrogen medical gas mixture Medical Gas Data Sheet (MGDS) 9% helium/35% oxygen/nitrogen medical gas mixture Essential safety information Summary of Product Characteristics (SPC) pages 2-7 Additional Safety Information pages 8-10

More information

1g cream or ointment contains 1 mg methylprednisolone aceponate.

1g cream or ointment contains 1 mg methylprednisolone aceponate. CONSUMER MEDICINE INFORMATION ADVANTAN 1g cream or ointment contains 1 mg methylprednisolone aceponate. What is in this leaflet Please read this leaflet carefully before you start using ADVANTAN. It will

More information

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC

More information

AXIRON (AXE-e-RON) CIII

AXIRON (AXE-e-RON) CIII Medication Guide 1 AXIRON (AXE-e-RON) CIII (testosterone) topical solution Read this Medication Guide before you start using AXIRON and each time you get a refill. There may be new information. This information

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:

More information

Omeprazole 20 mg gastro-resistant tablets PL 14017/0277

Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale

More information

Salbutamol 1mg/ml Nebuliser Solution. Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036

Salbutamol 1mg/ml Nebuliser Solution. Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036 Salbutamol 1mg/ml Nebuliser Solution Salbutamol 2mg/ml Nebuliser Solution PL 36390/0035 PL 36390/0036 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment

More information

ANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS ANNEX 1 SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cimalgex 8 mg chewable tablets for dogs Cimalgex 30 mg chewable tablets for dogs Cimalgex 80 mg chewable tablets

More information

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof; DIRECTIVE 65/65/EEC Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of

More information

Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse have told you.

Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse have told you. leaflet: Information for the user Macrogol 4000 10 g powder for oral solution in sachet Macrogol 4000

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION Temporary Core Product Information Inde- (13May2013) Page 1 / 7 1 NAME OF THE MEDICINAL PRODUCT XYLONOR SPRAY, oromucosal spray, solution. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains:

More information

One vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml.

One vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetor 100 U/ml powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 500 U* of

More information

Community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl.

Community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Schott et Endl. 22 November 2011 EMA/HMPC/722367/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Cola nitida (Vent.) Schott et Endl. and its varieties and Cola acuminata (P. Beauv.) Final

More information

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Nausicalm Cyclizine hydrochloride Ph. Eur. 50 mg Presentation White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Uses Actions The active ingredient-cyclizine

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start

More information

Kalms Tablets THR 01074/0235 UKPAR

Kalms Tablets THR 01074/0235 UKPAR Kalms Tablets THR 01074/0235 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Patient Information Leaflet

More information

MEDICATION GUIDE testosterone gel Testosterone (tes-tos-te-rone gel) CIII

MEDICATION GUIDE testosterone gel Testosterone (tes-tos-te-rone gel) CIII MEDICATION GUIDE testosterone gel Testosterone (tes-tos-te-rone gel) CIII Read this Medication Guide that comes with testosterone gel before you start using it and each time you get a refill. There may

More information

(NON-PRESCRIPTION) LEAFLET: USER INFORMATION. CALTRATE VITAMIN D3 600mg/400 IU, film-coated tablet Calcium and Cholecalciferol

(NON-PRESCRIPTION) LEAFLET: USER INFORMATION. CALTRATE VITAMIN D3 600mg/400 IU, film-coated tablet Calcium and Cholecalciferol (NON-PRESCRIPTION) LEAFLET: USER INFORMATION CALTRATE VITAMIN D3 600mg/400 IU, film-coated tablet Calcium and Cholecalciferol Read all of this leaflet carefully because it contains important information

More information

CORE SmPC FOR RADIOPHARMACEUTICALS

CORE SmPC FOR RADIOPHARMACEUTICALS CORE SmPC FOR RADIOPHARMACEUTICALS The QRD Product Information template with explanatory notes and the convention to be followed for QRD templates provide general guidance on format and text and should

More information

Safety Data Sheet Avesta Neutralization Agent 502

Safety Data Sheet Avesta Neutralization Agent 502 Safety Data Sheet Avesta Neutralization Agent 502 This Safety Data Sheet contains information to help users understand the potential hazards relating to this product and provides advice for risk management.

More information

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (WELL-ESTABLISHED MEDICINAL USE)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (WELL-ESTABLISHED MEDICINAL USE) European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101304/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON

More information

DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314

DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

InVita D3 25,000 IU oral solution PL 24837/0039

InVita D3 25,000 IU oral solution PL 24837/0039 InVita D3 25,000 IU oral solution PL 24837/0039 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Page 12 Summary of Product Characteristics Page 13 Patient

More information

PATIENT INFORMATION LEAFLET. CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN

PATIENT INFORMATION LEAFLET. CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN PATIENT INFORMATION LEAFLET CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Aviticol 800 IU Capsules Colecalciferol 800 IU Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains: 800 IU Colecalciferol

More information

MATERIAL SAFETY DATA SHEET PAGE 1

MATERIAL SAFETY DATA SHEET PAGE 1 1254 Chestnut Street Newton, MA 02464-1418 Tel: (617) 965-5511 Fax: (617) 965-5818 MATERIAL SAFETY DATA SHEET PAGE 1 SECTION 1. CHEMICAL IDENTIFICATION ---------------------------------------------------------

More information

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440 The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440 HAVRIX 720 Junior Monodose TITLE Hepatitis A (inactivated) vaccine

More information

Summary of Product Characteristics Medical Air

Summary of Product Characteristics Medical Air Summary of Product Characteristics Medical Air www.uk.airliquide.com 1. NAME OF THE MEDICINAL PRODUCT Medical Air 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Air Ph.Eur. 100% 3. PHARMACEUTICAL FORM Inhalation

More information

Medication Guide Testim (TĔS tim) CIII (testosterone gel)

Medication Guide Testim (TĔS tim) CIII (testosterone gel) Medication Guide Testim (TĔS tim) CIII (testosterone gel) Read this Medication Guide that comes with Testim before you start using it and each time you get a refill. There may be new information. This

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prednicare Tablets 5mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active Substance(s) Prednisolone

More information

MATERIAL SAFETY DATA SHEET TOILET BOWL SANITIZER

MATERIAL SAFETY DATA SHEET TOILET BOWL SANITIZER MATERIAL SAFETY DATA SHEET TOILET BOWL SANITIZER No. 1 Date Issued: 07/03/2011 COMPANY DETAILS NAME: Hygiene Systems (Pty) Ltd EMERGENCY TEL: 0860 494 4363 ADDRESS: 7 Hargan Road, TEL: 011 552 8403 SECTION

More information

1. IDENTIFICATION OF SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING.

1. IDENTIFICATION OF SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. P a g e 1 1. IDENTIFICATION OF SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. 2925 MFG Place Ashtabula, OH 44005 Emergency Telephone Number 1-800-424-9300 Regulatory Information Number 1-440-994-5207

More information

Public Assessment Report. Table of Contents

Public Assessment Report. Table of Contents Public Assessment Report Lidocaine Injection BP with preservative 1% Lidocaine Injection BP with preservative 2% PL 01502/0070 PL 01502/0071 Hameln Pharmaceuticals Limited Table of Contents Page Lay Summary

More information

RETIRIDES - Information for the user and usage instructions Translated from Spanish by Vaughter Wellness Ltd.

RETIRIDES - Information for the user and usage instructions Translated from Spanish by Vaughter Wellness Ltd. RETIRIDES - Information for the user and usage instructions Translated from Spanish by Vaughter Wellness Ltd. Table of Contents 1. Name of the product...2 2. Qualitative and quantitative composition...2

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin. Albuman 200 g/l SPC 01 December 2015 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albuman 200 g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albuman 200 g/l

More information

1. NAME OF THE MEDICINAL PRODUCT. Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. 1 capsule contains:

1. NAME OF THE MEDICINAL PRODUCT. Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. 1 capsule contains: 1. NAME OF THE MEDICINAL PRODUCT Impavido 10 mg capsules Impavido 50 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 capsule contains: Impavido 10 mg capsules 10 mg Miltefosine. Impavido 50 mg

More information

Ginkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR

Ginkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR Ginkgoforce Ginkgo biloba tablets THR 13668/0016 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 13 Summary of product characteristics Page 14 Product

More information

Ascorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287

Ascorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287 Ascorbic Acid 50 mg Tablets Ascorbic Acid 100 mg Tablets Ascorbic Acid 200 mg Tablets Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287 PL 20416/0288 PL 20416/0289 UKPAR TABLE OF CONTENTS Lay Summary

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol PACKAGE LEAFLET: INFORMATION FOR THE USER Paracetamol 500 mg Effervescent Tablets Paracetamol Read all of this leaflet carefully because it contains important information for you. This medicine is available

More information

ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS

ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken after authorisation

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS Registration No. : 2C 22/47 (N) Importer / Manufacturer: Sanofi Pasteur Ltd., Thailand/Sanofi Pasteur S.A., France SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT : PENTAXIM (Diphtheria,

More information

Package leaflet: Information for the patient. Bricanyl Tablets 5 mg terbutaline sulfate

Package leaflet: Information for the patient. Bricanyl Tablets 5 mg terbutaline sulfate Package leaflet: Information for the patient Bricanyl Tablets 5 mg terbutaline sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

CODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS

CODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS CODEINE PHOSPHATE 15 MG TABLETS CODEINE PHOSPHATE 30 MG TABLETS CODEINE PHOSPHATE 60 MG TABLETS PL 24837/0023-5 UK PAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for

More information

SDS. GHS Safety Data Sheet. Wechem, Inc. Extract All PRODUCT AND COMPANY IDENTIFICATION. Manufacturer HAZARDS IDENTIFICATION

SDS. GHS Safety Data Sheet. Wechem, Inc. Extract All PRODUCT AND COMPANY IDENTIFICATION. Manufacturer HAZARDS IDENTIFICATION Page 1 of 5 1 PRODUCT AND COMPANY IDENTIFICATION Manufacturer Wechem, Inc 5734 Susitna Dr Harahan, LA 70123 Contact: Phone: Fax: Web: Ligia M. Hernandez 504-733-1152 504-733-2218 www.wechem.com Product

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Eskazole Tablets 400 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Albendazole 400 mg Excipients with known effect: Lactose, sunset yellow

More information

Medication Guide ANDROGEL (AN DROW JEL) CIII (testosterone gel) 1%

Medication Guide ANDROGEL (AN DROW JEL) CIII (testosterone gel) 1% Medication Guide ANDROGEL (AN DROW JEL) CIII (testosterone gel) 1% Read this Medication Guide that comes with ANDROGEL 1% before you start taking it and each time you get a refill. There may be new information.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (HCl) STEROP 0,8mg/1ml. Solution for injection. Adrenaline (Levorenine, Epinephrine)

PACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (HCl) STEROP 0,8mg/1ml. Solution for injection. Adrenaline (Levorenine, Epinephrine) PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (HCl) STEROP 0,4mg/1ml ADRENALINE (HCl) STEROP 0,8mg/1ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Omega 3-acid-ethyl esters 1000mg soft capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One capsule contains 1000 mg Omega-3-Acid Ethyl

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Elidel 10 mg/g Cream. pimecrolimus

PACKAGE LEAFLET: INFORMATION FOR THE USER. Elidel 10 mg/g Cream. pimecrolimus PACKAGE LEAFLET: INFORMATION FOR THE USER Elidel 10 mg/g Cream pimecrolimus Read all of this leaflet carefully before you start using Elidel cream Keep this leaflet. You may need to read it again. If you

More information

COMPOSITION / INFORMATION ON INGREDIENTS

COMPOSITION / INFORMATION ON INGREDIENTS MATERIAL SAFETY DATA SHEET DAMTITE WATERPROOFER- WHITE 01071, 01211, 01451 DAMTITE POWDER FOUNDATION WATERPROOFER GRAY 02451 SECTION I. COMPANY & PRODUCT INFORMATION Product Identification Manufacturer

More information

Community herbal monograph on Cucurbita pepo L., semen

Community herbal monograph on Cucurbita pepo L., semen 20 November 2012 EMA/HMPC/136024/2010 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Cucurbita pepo L., semen Final Discussion in Working Party on Community monographs and

More information

1.3.1.3 PACKAGE LEAFLET

1.3.1.3 PACKAGE LEAFLET Sandoz Business use only Page 1 of 8 1.3.1.3 PACKAGE LEAFLET Sandoz Business use only Page 2 of 8 Package leaflet: Information for the patient Cefuhexal 250 mg film-coated tablets Cefuhexal 500 mg film-coated

More information

Community herbal monograph on Primula veris L. and/or Primula elatior (L.) Hill, flos

Community herbal monograph on Primula veris L. and/or Primula elatior (L.) Hill, flos 19 September 2012 EMA/HMPC/136582/2012 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Primula veris L. and/or Primula elatior (L.) Hill, flos Final Initial assessment Discussion

More information

Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum

Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., oleum 16 December 2011 EMA/HMPC/277792/2009 Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Oenothera biennis L.; Oenothera lamarckiana L., Final Discussion in Working Party on Community

More information

Medical Gas Data Sheet (MGDS) 9% helium/35% oxygen/ nitrogen medical gas mixture

Medical Gas Data Sheet (MGDS) 9% helium/35% oxygen/ nitrogen medical gas mixture Medical Gas Data Sheet (MGDS) Medical Gas Data Sheet (MGDS) 9% helium/35% oxygen/ nitrogen medical gas mixture Essential safety information BOC: Living healthcare 02 9% helium/35% oxygen/nitrogen medical

More information

PL 17871/0208 UKPAR TABLE OF CONTENTS

PL 17871/0208 UKPAR TABLE OF CONTENTS Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

Medical Gas Data Sheet (MGDS) Medical air

Medical Gas Data Sheet (MGDS) Medical air Medical Gas Data Sheet (MGDS) Medical air Essential safety information Summary of Product Characteristics (SPC) pages 2-6 Additional Safety Information pages 7-8 BOC: Living healthcare 2 Medical air SPC

More information

Arnicare Arnica 30c pillules NR 01175/0181 UKPAR

Arnicare Arnica 30c pillules NR 01175/0181 UKPAR Arnicare Arnica 30c pillules NR 01175/0181 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of product characteristics Page 12 Product

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Trihexyphenidyl 2mg Tablets BP 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg of trihexyphenidyl hydrochloride BP

More information

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride A leaflet will be included in each pack. The leaflet will consist of a Technical Information Leaflet and a Patient Information Leaflet. The two leaflets will be easily separatable. The text of the Technical

More information

Sodium Aluminum Tetrafluoride

Sodium Aluminum Tetrafluoride In an emergency, call CHEMTREC at 800-424-9300 or MEMC Pasadena at 713-740-1501 NaAlF 4 HEALTH FLAMMABILITY 2 0 2 0 0 PHYSICAL HAZARD 0 PERSONAL PROTECTION SECTION 1: CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

More information

SR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1

SR 5. W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1 W2364A_NT.XATRAL SR5 PAK/SA 5/12/05 9:47 Page 1 alfuzosin SR 5 mg (Alfuzosin HCI) COMPOSITION Each sustained-release, film-coated tablet contains: Alfuzosin hydrochloride......... 5 mg Excipients... q.s.

More information